IDEXX Laboratories, Inc. $IDXX Shares Sold by Vontobel Holding Ltd.

Vontobel Holding Ltd. lowered its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 413,534 shares of the company’s stock after selling 43,087 shares during the quarter. Vontobel Holding Ltd. owned about 0.51% of IDEXX Laboratories worth $221,795,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD grew its stake in IDEXX Laboratories by 71.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock valued at $835,244,000 after purchasing an additional 825,965 shares in the last quarter. Select Equity Group L.P. acquired a new stake in IDEXX Laboratories during the 1st quarter valued at approximately $194,834,000. Nuveen LLC acquired a new stake in IDEXX Laboratories during the 1st quarter valued at approximately $179,784,000. Principal Financial Group Inc. grew its stake in IDEXX Laboratories by 58.3% during the 1st quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company’s stock valued at $472,865,000 after purchasing an additional 414,802 shares in the last quarter. Finally, Durable Capital Partners LP acquired a new stake in IDEXX Laboratories during the 1st quarter valued at approximately $153,180,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Piper Sandler restated a “neutral” rating and set a $700.00 price objective (up previously from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of IDEXX Laboratories in a report on Wednesday. JPMorgan Chase & Co. increased their target price on IDEXX Laboratories from $550.00 to $675.00 and gave the stock an “overweight” rating in a report on Monday, August 4th. BTIG Research raised their price target on IDEXX Laboratories from $545.00 to $785.00 and gave the stock a “buy” rating in a report on Tuesday, August 5th. Finally, UBS Group started coverage on IDEXX Laboratories in a report on Wednesday, October 1st. They issued a “neutral” rating and a $720.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $656.50.

IDEXX Laboratories Stock Up 0.4%

Shares of IDXX stock opened at $629.91 on Thursday. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $688.12. The stock has a market cap of $50.40 billion, a PE ratio of 52.45, a price-to-earnings-growth ratio of 4.06 and a beta of 1.58. The business’s fifty day moving average is $637.99 and its 200-day moving average is $539.07. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.35. The company had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same period last year, the firm earned $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Activity at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 1,200 shares of IDEXX Laboratories stock in a transaction on Monday, August 11th. The stock was sold at an average price of $656.53, for a total transaction of $787,836.00. Following the transaction, the executive vice president owned 16,807 shares in the company, valued at approximately $11,034,299.71. The trade was a 6.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Sharon E. Underberg sold 5,450 shares of the company’s stock in a transaction on Friday, August 8th. The shares were sold at an average price of $651.60, for a total value of $3,551,220.00. Following the transaction, the executive vice president directly owned 6,156 shares in the company, valued at $4,011,249.60. The trade was a 46.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 54,057 shares of company stock valued at $34,293,468 over the last ninety days. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.